Technical, ethical and social issues in the bioprediction of addiction liability and treatment response

Addiction Neuroethics: The ethics of addiction neuroscience research and treatment

Volumn , Issue , 2012, Pages 115-135

  Hall, Wayne D ^a   Gartner, Coral E ^a   Mathews, Rebecca ^a   Munafò, Marcus ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882829872     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-385973-0.00006-5     Document Type: Chapter

References (120)

1. Agrawal A., Lynskey M.T. Are there genetic influences on addiction? Evidence from family, adoption and twin studies. Addiction 2008, 103:1069-1081.
2. Anderlik M.R., Rothstein M.A. Privacy and confidentiality of genetic information: What rules for the new science?. Annual Review of Genomics and Human Genetics 2001, 2:401-433.
3. Anton R.F., O'Malley S., Ciraulo D.A., Cisler R.A., Couper D., Donovan D.M., et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial. Journal of the American Medical Association 2006, 295:2003-2017.
4. Anton R.F., Oroszi G., O'Malley S., Couper D., Swift R., Pettinati H., et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: Results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Archives of General Psychiatry 2008, 65:135-144.
5. Appelbaum P.S. Genetic discrimination in mental disorders: The impact of the genetic information non-discrimination act. Psychiatric Services 2010, 61:338-340.
6. Ashcroft R., Campbell A., Capps B. Ethical aspects of developments in neuroscience and drug addiction. Drugs and the future: Brain science, addiction and society 2007, 439-466. Academic Press, San Diego, CA. D. Nutt, T. Robbins, G. Stimson, M. Ince, A. Jackson (Eds.).
7. Audrain J., Boyd N.R., Roth J., Main D., Caporaso N.F., Lerman C. Genetic susceptibility testing in smoking-cessation treatment: One-year outcomes of a randomized trial. Addictive Behaviors 1997, 22:741-751.
8. Babor T., Miller P., Edwards G. Vested interests, addiction research and public policy. Addiction 2010, 105:4-5.
9. Backlar P. Genes and behavior: Will genetic information change the way we see ourselves?. Community Mental Health Journal 1996, 32:205-209.
10. Ball D., Pembrey M., Stevens D.N. Genomics. Drugs and the future: Brain science, addiction and society 2007, 89-131. Academic Press, San Diego, CA. D. Nutt, T.W. Robbins, G.V. Stimson, M. Ince, A. Jackson (Eds.).
11. BBC (2004, December 2). "DNA test" to help smokers quit. Retrieved April 23, 2007, from . http://www.news.bbc.co.uk/2/hi/health/4061137.stm.
12. 2 dopamine receptor taqI A polymorphism on smoking cessation. Nicotine and Tobacco Research 2005, 7:725-728.
13. Berrettini W.H., Lerman C.E. Pharmacotherapy and pharmacogenetics of nicotine dependence. American Journal of Psychiatry 2005, 162:1441-1451.
14. Berrettini W.H., Wileyto E.P., Epstein L., Restine S., Hawk L., Shields P., et al. Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biological Psychiatry 2007, 61:111-118.
15. Billings P.R., Kohn M.A., de Cuevas M., Beckwith J., Alper J.S., Natowicz M.R. Discrimination as a consequence of genetic testing. American Journal of Human Genetics 1992, 50:476-482.
16. Cappella J.N., Lerman C., Romantan A., Baruh L. News about genetics and smoking. Communication Research 2005, 32:478-502.
17. Carlsten C., Burke W. Potential for genetics to promote public health: Genetics research on smoking suggests caution about expectations. Journal of the American Medical Association 2006, 296:2480-2482.
18. Caron L., Karkazis K., Raffin T., Swan G., Koenig B. Nicotine addiction through a neurogenomic prism: Ethics, public health, and smoking. Nicotine and Tobacco Research 2005, 7:181-197.
19. Carpenter M.J., Strange C., Jones Y., Dickson M., Carter C., Moseley M.A., et al. Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for alpha-1 antitrypsin deficiency. Annals of Behavior Medicine 2007, 33:22-28.
20. Chapman S., MacKenzie R. The global research neglect of unassisted smoking cessation: Causes and consequences. Public Library of Science ONE 2010, 7(2). (e1000216).
21. Collins F.S. Shattuck Lecture-Medical and societal consequences of the Human Genome Project. New England Journal of Medicine 1999, 341:28-37.
22. Conrad P. Medicalization and social control. Annual Review of Sociology 1992, 18:209-232.
23. Cox W.M., Hogan L.M., Kristian M.R., Race J.H. Alcohol attentional bias as a predictor of alcohol abusers' treatment outcome. Drug and Alcohol Dependence 2002, 68:237-243.
24. 2 dopamine receptor (DRD2) and the neuronal calcium sensor-1 (FREQ) genes in predicting response to nicotine replacement therapy for tobacco dependence. Pharmacogenomics Journal 2006, 6:194-199.
25. Davey Smith G., Ebrahim S., Lewis S., Hansell A.L., Palmer L.J., Burton P.R. Genetic epidemiology 7-Genetic epidemiology and public health: Hope, hype, and future prospects. Lancet 2005, 366:1484-1498.
26. David S.P., Munafò M.R., Murphy M.F.G., Walton R.T., Johnstone E.C. The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: Follow-up of a randomized controlled trial. Nicotine and Tobacco Research 2007, 9:225-231.
27. De Francesco L. Genetic profiteering. Nature Biotechnology 2006, 24:888-890.
28. Doyle, C. (2004, December 3). DNA test can identify "the smoker's gene". Retrieved April 23, 2007, from . http://www.telegraph.co.uk/science/science-news/3336508/DNA-test-can-ide ntify-the-smokers-gene.html.
29. Evans J.P., Meslin E.M., Marteau T.M., Caulfield T. Genomics. Deflating the genomic bubble. Science 2011, 331:861-862.
30. Ezzati M., Lopez A.D. Estimates of global mortality attributable to smoking in 2000. Lancet 2003, 362:847-852.
31. Feldstein Ewing S.W., LaChance H.A., Bryan A., Hutchison K.E. Do genetic and individual risk factors moderate the efficacy of motivational enhancement therapy? Drinking outcomes with an emerging adult sample. Addiction Biology 2009, 14:356-365.
32. Flowers C.R., Veenstra D. The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics 2004, 22:481-493.
33. Fowler T., Lifford K., Shelton K., Rice F., Thapar A., Neale M.C., et al. Exploring the relationship between genetic and environmental influences on initiation and progression of substance use. Addiction 2007, 102:413-422.
34. Gartner C., Barendregt J., Hall W. Multiple genetic tests for susceptibility to smoking do not outperform simple family history. Addiction 2009, 104:118-126.
35. GeneWatch UK (2004). Three reasons not to buy the NicoTest genetic test. Retrieved April 12, 2007, from . http://www.genewatch.org/uploads/f03c6d66a9b354535738483c1c3d49e4/Nicote st_brief_final.pdf.
36. Geppert C., Roberts L.W. Ethical issues in the use of genetic information in the workplace: A review of recent developments. Current Opinion in Psychiatry 2005, 18:518-524.
37. Goldman D., Oroszi G., Ducci F. The genetics of addictions: Uncovering the genes. Nature Reviews Genetics 2005, 6:521-532.
38. Goudriaan A.E., Oosterlaan J., De Beurs E., Van Den Brink W. The role of self-reported impulsivity and reward sensitivity versus neurocognitive measures of disinhibition and decision-making in the prediction of relapse in pathological gamblers. Psychological Medicine 2008, 38:41-50.
39. Greely H. Genotype discrimination: The complex case for some legislative protection. University of Pennsylvania Law Review 2001, 149:1438-1505.
40. Greenbaum L., Lerer B. Differential contribution of genetic variation in multiple brain nicotinic cholinergic receptors to nicotine dependence: Recent progress and emerging open questions. Molecular Psychiatry 2009, 14:912-945.
41. Gundle K.R., Dingel M.J., Koenig B.A. 'To prove this is the industry's best hope': Big tobacco's support of research on the genetics of nicotine addiction. Addiction 2010, 105:974-983.
42. Hall M.A., Rich S.S. Laws restricting health insurers' use of genetic information: Impact on genetic discrimination. American Journal of Human Genetics 2000, 66:293-307.
43. Hall W. British drinking: A suitable case for treatment?. British Medical Journal 2005, 331:527-528.
44. Hall W. A research agenda for assessing the potential contribution of genomic medicine to tobacco control. Tobacco Control 2007, 16:53-58.
45. Hall W., Chikritzhs T. The Australian alcopops tax revisited. Lancet 2011, 377:1136-1137.
46. Hall W., Gartner C., Carter A. The genetics of nicotine addiction liability: Ethical and social policy implications. Addiction 2008, 103:347-352.
47. Hall W., Madden P., Lynskey M. The genetics of tobacco use: Methods, findings and policy implications. Tobacco Control 2002, 11:119-124.
48. Ho M.K., Goldman D., Heinz A., Kaprio J., Kreek M.J., Li M.D., et al. Breaking barriers in the genomics and pharmacogenetics of drug addiction. Clinical Pharmacology and Therapeutics 2010, 88:779-791.
49. Ho M.K., Tyndale R.F. Overview of the pharmacogenomics of cigarette smoking. Pharmacogenomics Journal 2007, 7:81-98.
50. Hoff, N., Evers-Casey, S., Weibel, S., Patkar, A., & Leone, F. (2005). Impact of genetic risk information on smokers' motivation to quit. 11th Annual Meeting of the Society for Research on Nicotine and Tobacco, RP-062, S16, Prague.
51. Hutchison K.E. Substance use disorders: Realizing the promise of pharmacogenomics and personalized medicine. Annual Review of Clinical Psychology 2010, 6:577-589.
52. Ioannidis J. Genetic associations: False or true?. Trends in Molecular Medicine 2003, 9:135-138.
53. Ioannidis J. Excess significance bias in the literature on brain volume abnormalities. Archives of General Psychiatry 2011, 68. (Epub April 4; doi:10.1001/archgenpsychiatry.2011.28).
54. Ioannidis J., Trikalinos T.A., Ntzani E.E., Contopoulos-Ioannidis D.G. Genetic associations in large versus small studies: An empirical assessment. Lancet 2003, 361:567-571.
55. Ito H., Matsuo K., Wakai K., Saito T., Kumimoto H., Okuma K., et al. An intervention study of smoking cessation with feedback on genetic cancer susceptibility in Japan. Preventive Medicine 2006, 42:102-108.
56. John U., Meyer C., Hapke U., Rumpf H.-J., Schumanna A. Nicotine dependence, quit attempts, and quitting among smokers in a regional population sample from a country with a high prevalence of tobacco smoking. Preventive Medicine 2004, 38:350-358.
57. Johnstone E.C., Yudkin P.L., Hey K., Roberts S.J., Welch S.J., Murphy M.F., et al. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 2004, 14:83-90.
58. Joly Y., Braker M., Le Huynh M. Genetic discrimination in private insurance: Global perspectives. New Genetics and Society 2010, 29:351-368.
59. Kendler K.S., Prescott C.A. Genes, environment and psychopathology: Understanding the causes of psychiatric and substance use disorders 2006, Guildford Press, New York.
60. Khoury M.J. Genetics and genomics in practice: The continuum from genetic disease to genetic information in health and disease. Genetics in Medicine 2003, 5:261-268.
61. Khoury M.J., Davis R., Gwinn M., Lindegren M.L., Yoon P. Do we need genomic research for the prevention of common diseases with environmental causes?. American Journal of Epidemiology 2005, 161:799-805.
62. Khoury M.J., Thrasher J.F., Burke W., Gettig E.A., Fridinger F., Jackson R. Challenges in communicating genetics: A public health approach. Genetics in Medicine 2000, 2:198-202.
63. Khoury M.J., Yang Q., Gwinn M., Little J., Flanders W.D. An epidemiologic assessment of genomic profiling for measuring susceptibility to common diseases and targeting interventions. Genetics in Medicine 2004, 6:38-47.
64. Kuehn B.M. Findings on alcohol dependence point to promising avenues for targeted therapies. Journal of the American Medical Association 2009, 301:1643-1645.
65. Lee A.M., Tyndale R.F. Drugs and genotypes: How pharmacogenetic information could improve smoking cessation treatment. Journal of Psychopharmacology 2006, 20(4 Suppl.):7-14.
66. Lerman C., Gold K., Audrain J., Lin T.H., Boyd N.R., Orleans C.T., et al. Incorporating biomarkers of exposure and genetic susceptibility into smoking cessation treatment: Effects on smoking-related cognitions, emotions, and behavior change. Health Psychology 1997, 16:87-99.
67. 2) in response to bupropion and nicotine replacement therapy for tobacco dependence: Results of two randomized clinical trials. Neuropsychopharmacology 2006, 31:231-242.
68. Lerman C., Shields P.G., Wileyto E.P., Audrain J., Hawk L.H., Pinto A., et al. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychology 2003, 22:541-548.
69. Lerman C., Shields P.G., Wileyto E.P., Audrain J., Pinto A., Hawk L., et al. Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics 2002, 12:627-634.
70. Lerman C., Wileyto E.P., Patterson F., Rukstalis M., Audrain-McGovern J., Restine S., et al. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics Journal 2004, 4:184-192.
71. Li M.D., Burmeister M. New insights into the genetics of addiction. Nature Reviews. Genetics 2009, 10:225-231.
72. Li M.D., Cheng R., Ma J.Z., Swan G.E. A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. Addiction 2003, 98:23-31.
73. Li M.D., Ma J.Z., Beuten J. Progress in searching for susceptibility loci and genes for smoking-related behavior. Clinical Genetics 2004, 66:382-392.
74. Marteau T.M., Lerman C. Genetic risk and behavioral change. British Medical Journal 2001, 322:1056-1059.
75. Marteau T., Munafò M.R., Aveyard P., Hill C., Whitwell S., Willis T., et al. Trial protocol: Using genotype to tailor prescribing of nicotine replacement therapy: A randomised controlled trial assessing impact of communication upon adherence. BMC Public Health 2010, 10:680.
76. The troubled helix: Social and psychological implications of the new genetics 1996, Cambridge University Press, Cambridge. T.M. Marteau, D. Richards (Eds.).
77. McBride C.M., Bepler G., Lipkus I.M., Lyna P., Samsa G., Albright J., et al. Incorporating genetic susceptibility feedback into a smoking cessation program for African-American smokers with low income. Cancer Epidemiology, Biomarkers and Prevention 2002, 11:521-528.
78. McBride C.M., Bowen D., Brody L.C., Condit C.M., Croyle R.T., Gwinn M., et al. Future health applications of genomics: Priorities for communication, behavioral, and social sciences research. American Journal of Preventive Medicine 2010, 38:556-565.
79. Merikangas K.R., Risch N. Genomic priorities and public health. Science 2003, 302:599-601.
80. Miller W.R., Walters S.T., Bennett M.E. How effective is alcoholism treatment in the United States?. Journal of Studies on Alcohol 2001, 62:211-220.
81. Munafò M.R. The clinical utility of genetic tests. Addiction 2009, 104:127-128.
82. Munafò M.R. Reliability and replicability of genetic association studies. Addiction 2009, 104:1439-1440.
83. Munafò M.R., Clark T.G., Johnstone E.C., Murphy M.F.G., Walton R.T. The genetic basis for smoking behavior: A systematic review and meta-analysis. Nicotine and Tobacco Research 2004, 6:583-598.
84. Munafò M.R., Elliot K.M., Murphy M.F.G., Walton R.T., Johnstone E.C. Association of the mu-opioid receptor gene with smoking cessation. Pharmacogenomics Journal 2007, 7:353-361.
85. Munafò M.R., Johnstone E.C., Wileyto E.P., Shields P.G., Elliot K.M., Lerman C. Lack of association of 5-HTTLPR genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiology, Biomarkers and Prevention 2006, 15:398-400.
86. Munafò M.R., Matheson I.J., Flint J. Association of the DRD2 gene Taq1A polymorphism and alcoholism: A meta-analysis of case-control studies and evidence of publication bias. Molecular Psychiatry 2007, 12:454-461.
87. Munafò M.R., Shields A.E., Berrettini W.H., Patterson F., Lerman C. Pharmacogenetics and nicotine addiction treatment. Pharmacogenomics 2005, 6:211-223.
88. Munafò M.R., Timpson N.J., David S.P., Ebrahim S., Lawlor D.A. Association of the DRD2 gene Taq1A polymorphism and smoking behavior: A meta-analysis and new data. Nicotine and Tobacco Research 2009, 11:64-76.
89. Ng P.C., Murray S.S., Levy S., Venter J.C. An agenda for personalized medicine. Nature 2009, 461:724-726.
90. Ooteman W., Naassila M., Koeter M.W., Verheul R., Schippers G.M., Houchi H., et al. Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addiction Biology 2009, 14:328-337.
91. Oroszi G., Anton R.F., O'Malley S., Swift R., Pettinati H., Couper D., et al. OPRM1 Asn40Asp predicts response to naltrexone treatment: A haplotype-based approach. Alcoholism: Clinical and Experimental Research 2009, 33:383-393.
92. Oslin D.W., Berrettini W.H., O'Brien C.P. Targeting treatments for alcohol dependence: The pharmacogenetics of naltrexone. Addiction Biology 2006, 11:397-403.
93. Paulus M.P., Tapert S.F., Schuckit M.A. Neural activation patterns of methamphetamine-dependent subjects during decision making predict relapse. Archives of General Psychiatry 2005, 62:761-768.
94. Pierce J.P., Gilpin E.A., Emery S.L., White M.M., Rosbrook B., Berry C.C. Has the California Tobacco Control Program reduced smoking?. Journal of the American Medical Association 1998, 280:893-899.
95. Press N. Social construction and medicalization: Behavioral genetics in context. Wrestling with behavioral genetics: Science, ethics and public conversation 2006, 131-149. Johns Hopkins University Press, Baltimore, MD. E. Parens, A.R. Chapman, N. Press (Eds.).
96. Ray L.A., Hutchison K.E. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: A double-blind placebo-controlled study. Archives of General Psychiatry 2007, 64:1069-1077.
97. Ray L.A., Miranda R., MacKillop J., McGeary J., Tidey J.W., Rohsenow D.J., et al. A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Experimental and Clinical Psychopharmacology 2009, 17:122-129.
98. Rothenberg K., Fuller B., Rothstein M., Duster T., Kahn M.J.E., Cunningham R., et al. Genetic information and the workplace: Legislative approaches and policy challenges. Science 1997, 275:1755-1757.
99. Rothstein M.A. Genetic privacy and confidentiality: Why they are so hard to protect. Journal of Law, Medicine and Ethics 1998, 26:198-204.
100. Rothstein M.A. Putting the Genetic Information Nondiscrimination Act in context. Genetics in Medicine 2008, 10:655-656.
101. Rothstein M.A., Anderlik M.R. What is genetic discrimination, and when and how can it be prevented?. Genetics in Medicine 2001, 3:354-358.
102. Schutz C.G. Using neuroimaging to predict relapse to smoking: Role of possible moderators and mediators. International Journal of Methods in Psychiatric Research 2008, 17(Suppl. 1):S78-S82.
103. Singh I., Rose N. Biomarkers in psychiatry. Nature 2009, 460:202-207.
104. Smith L., Watson M., Gates S., Ball D., Foxcroft D. Meta-analysis of the association of the Taq1A polymorphism with the risk of alcohol dependency: A HuGE gene-disease association review. American Journal of Epidemiology 2008, 167:125-138.
105. Taylor S. A case study of genetic discrimination: Social work and advocacy within a new context. Australian Social Work 1998, 51:51-57.
106. Taylor S., Treloar S., Barlow-Stewart K., Stranger M., Otlowski M. Investigating genetic discrimination in Australia: A large-scale survey of clinical genetics clients. Clinical Genetics 2008, 74:20-30.
107. Tercyak K.P., Peshkin B.N., Abraham A., Wine L., Walker L.R. Interest in genetic counseling and testing for adolescent nicotine addiction susceptibility among a sample of adolescent medicine providers attending a scientific conference on adolescent health. Journal of Adolescent Health 2007, 41:42-50.
108. Tercyak K.P., Peshkin B.N., Wine L.A., Walker L.R. Interest of adolescents in genetic testing for nicotine addiction susceptibility. Preventive Medicine 2006, 42:60-65.
109. Udesky L. The ethics of direct-to-consumer genetic testing. Lancet 2010, 376:1377-1378.
110. Uhl G., Grow R.W. The burden of complex genetics in brain disorders. Archives of General Psychiatry 2004, 61:223-229.
111. Van Hoyweghen I., Horstman K. European practices of genetic information and insurance: Lessons for the Genetic Information Nondiscrimination Act. Journal of the American Medical Association 2008, 300:326-327.
112. Verweij M. Medicalization as a moral problem for preventive medicine. Bioethics 1999, 13:89-113.
113. Vink J.M., Willemsen G., Boomsma D.I. Heritability of smoking initiation and nicotine dependence. Behavior Genetics 2005, 35:397-406.
114. Volkow N., Li T.K. The neuroscience of addiction. Nature Neuroscience 2005, 8:1429-1430.
115. Vrecko S. Capital ventures into biology: Biosocial dynamics in the industry and science of gambling. Economy and Society 2008, 37:50-67.
116. Welton N.J., Johnstone E.C., David S.P., Munafò M.R. A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation. Nicotine and Tobacco Research 2008, 10:231-240.
117. White V., Hill D., Siahpush M., Bobevski I. How has the prevalence of cigarette smoking changed among Australian adults? Trends in smoking prevalence between 1980 and 2001. Tobacco Control 2003, 12(Suppl. II):ii67-ii74.
118. Wilfond B.S., Geller G., Lerman C., Audrain-McGovern J., Shields A. Ethical issues in conducting behavioral genetics research: The case of smoking prevention trials among adolescents. Journal of Health Care Law & Policy 2002, 6:73-88.
119. Willett W. Balancing life-style and genomics research for disease prevention. Science 2002, 296:695-698.
120. Wright A.J., Weinman J., Marteau T.M. The impact of learning of a genetic predisposition to nicotine dependence: An analogue study. Tobacco Control 2003, 12:227-230.